Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)

ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in ...
News Medical

VT3989 shows promising antitumor activity in refractory mesothelioma patients

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to ...
KTLA

BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors

SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in developing covalent small molecule drugs for traditional "hard-to-drug" targets, announced today that the first ...
EurekAlert!

Insilico Medicine announces first patient dosed in phase I clinical trial of ISM6331, the novel inhibitor for the treatment of mesothelioma and other solid tumors

The global multicenter Phase I trial of ISM6331 that is enrolling patients in China and the United States has advanced with the dosing of the first patient in this study for the treatment of ...